Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
Randomization of patients in the world’s first Phase 3 oral insulin study conducted under FDA approved protocol NEW YORK, Jan. 21, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 […]
